Cancer Screening Technology - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB511248871

Publication Date:

November 27, 2024

Pages:

130

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global market for Cancer Screening Technology was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Cancer Screening Technology was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Cancer Screening Technology was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Cancer Screening Technology was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Cancer Screening Technology include Abbott, BD, Siemens Healthineers, GE Healthcare, F. Hoffmann-La Roche, Olympus Corporation, FUJIFILM Corporation, Agilent Technologies and Eiken Chemical, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Cancer Screening Technology, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Cancer Screening Technology by region & country, by Type, and by Application.
The Cancer Screening Technology market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Screening Technology.
麻豆原创 Segmentation
By Company
Abbott
BD
Siemens Healthineers
GE Healthcare
F. Hoffmann-La Roche
Olympus Corporation
FUJIFILM Corporation
Agilent Technologies
Eiken Chemical
Hitachi Chemical (Kyowa Medex)
Clinical Genomics Pty Ltd (Quest Diagnostics)
Sysmex
QIAGEN
R-Biopharm
Immunostics
Segment by Type:
Instrument-based Inspection
Platform-based Inspection
Segment by Application
Lung Cancer Screening
Breast Cancer Screening
Prostate Cancer Screening
Colorectal Cancer Screening
Blood Cancer Screening
Liver Cancer Screening
Pancreatic Cancer Screening
Skin Cancer Screening
Cervical Cancer Screening
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Cancer Screening Technology manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Cancer Screening Technology in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Cancer Screening Technology in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Cancer Screening Technology Product Introduction
1.2 Global Cancer Screening Technology 麻豆原创 Size Forecast
1.3 Cancer Screening Technology 麻豆原创 Trends & Drivers
1.3.1 Cancer Screening Technology Industry Trends
1.3.2 Cancer Screening Technology 麻豆原创 Drivers & Opportunity
1.3.3 Cancer Screening Technology 麻豆原创 Challenges
1.3.4 Cancer Screening Technology 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Cancer Screening Technology Players Revenue Ranking (2023)
2.2 Global Cancer Screening Technology Revenue by Company (2019-2024)
2.3 Key Companies Cancer Screening Technology Manufacturing Base Distribution and Headquarters
2.4 Key Companies Cancer Screening Technology Product Offered
2.5 Key Companies Time to Begin Mass Production of Cancer Screening Technology
2.6 Cancer Screening Technology 麻豆原创 Competitive Analysis
2.6.1 Cancer Screening Technology 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Cancer Screening Technology Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Screening Technology as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Instrument-based Inspection
3.1.2 Platform-based Inspection
3.2 Global Cancer Screening Technology Sales Value by Type
3.2.1 Global Cancer Screening Technology Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Cancer Screening Technology Sales Value, by Type (2019-2030)
3.2.3 Global Cancer Screening Technology Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Lung Cancer Screening
4.1.2 Breast Cancer Screening
4.1.3 Prostate Cancer Screening
4.1.4 Colorectal Cancer Screening
4.1.5 Blood Cancer Screening
4.1.6 Liver Cancer Screening
4.1.7 Pancreatic Cancer Screening
4.1.8 Skin Cancer Screening
4.1.9 Cervical Cancer Screening
4.1.10 Other
4.2 Global Cancer Screening Technology Sales Value by Application
4.2.1 Global Cancer Screening Technology Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Cancer Screening Technology Sales Value, by Application (2019-2030)
4.2.3 Global Cancer Screening Technology Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Cancer Screening Technology Sales Value by Region
5.1.1 Global Cancer Screening Technology Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Cancer Screening Technology Sales Value by Region (2019-2024)
5.1.3 Global Cancer Screening Technology Sales Value by Region (2025-2030)
5.1.4 Global Cancer Screening Technology Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Cancer Screening Technology Sales Value, 2019-2030
5.2.2 North America Cancer Screening Technology Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Cancer Screening Technology Sales Value, 2019-2030
5.3.2 Europe Cancer Screening Technology Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Cancer Screening Technology Sales Value, 2019-2030
5.4.2 Asia Pacific Cancer Screening Technology Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Cancer Screening Technology Sales Value, 2019-2030
5.5.2 South America Cancer Screening Technology Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Cancer Screening Technology Sales Value, 2019-2030
5.6.2 Middle East & Africa Cancer Screening Technology Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Cancer Screening Technology Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Cancer Screening Technology Sales Value
6.3 United States
6.3.1 United States Cancer Screening Technology Sales Value, 2019-2030
6.3.2 United States Cancer Screening Technology Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Cancer Screening Technology Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Cancer Screening Technology Sales Value, 2019-2030
6.4.2 Europe Cancer Screening Technology Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Cancer Screening Technology Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Cancer Screening Technology Sales Value, 2019-2030
6.5.2 China Cancer Screening Technology Sales Value by Type (%), 2023 VS 2030
6.5.3 China Cancer Screening Technology Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Cancer Screening Technology Sales Value, 2019-2030
6.6.2 Japan Cancer Screening Technology Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Cancer Screening Technology Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Cancer Screening Technology Sales Value, 2019-2030
6.7.2 South Korea Cancer Screening Technology Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Cancer Screening Technology Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Cancer Screening Technology Sales Value, 2019-2030
6.8.2 Southeast Asia Cancer Screening Technology Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Cancer Screening Technology Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Cancer Screening Technology Sales Value, 2019-2030
6.9.2 India Cancer Screening Technology Sales Value by Type (%), 2023 VS 2030
6.9.3 India Cancer Screening Technology Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Abbott
7.1.1 Abbott Profile
7.1.2 Abbott Main Business
7.1.3 Abbott Cancer Screening Technology Products, Services and Solutions
7.1.4 Abbott Cancer Screening Technology Revenue (US$ Million) & (2019-2024)
7.1.5 Abbott Recent Developments
7.2 BD
7.2.1 BD Profile
7.2.2 BD Main Business
7.2.3 BD Cancer Screening Technology Products, Services and Solutions
7.2.4 BD Cancer Screening Technology Revenue (US$ Million) & (2019-2024)
7.2.5 BD Recent Developments
7.3 Siemens Healthineers
7.3.1 Siemens Healthineers Profile
7.3.2 Siemens Healthineers Main Business
7.3.3 Siemens Healthineers Cancer Screening Technology Products, Services and Solutions
7.3.4 Siemens Healthineers Cancer Screening Technology Revenue (US$ Million) & (2019-2024)
7.3.5 GE Healthcare Recent Developments
7.4 GE Healthcare
7.4.1 GE Healthcare Profile
7.4.2 GE Healthcare Main Business
7.4.3 GE Healthcare Cancer Screening Technology Products, Services and Solutions
7.4.4 GE Healthcare Cancer Screening Technology Revenue (US$ Million) & (2019-2024)
7.4.5 GE Healthcare Recent Developments
7.5 F. Hoffmann-La Roche
7.5.1 F. Hoffmann-La Roche Profile
7.5.2 F. Hoffmann-La Roche Main Business
7.5.3 F. Hoffmann-La Roche Cancer Screening Technology Products, Services and Solutions
7.5.4 F. Hoffmann-La Roche Cancer Screening Technology Revenue (US$ Million) & (2019-2024)
7.5.5 F. Hoffmann-La Roche Recent Developments
7.6 Olympus Corporation
7.6.1 Olympus Corporation Profile
7.6.2 Olympus Corporation Main Business
7.6.3 Olympus Corporation Cancer Screening Technology Products, Services and Solutions
7.6.4 Olympus Corporation Cancer Screening Technology Revenue (US$ Million) & (2019-2024)
7.6.5 Olympus Corporation Recent Developments
7.7 FUJIFILM Corporation
7.7.1 FUJIFILM Corporation Profile
7.7.2 FUJIFILM Corporation Main Business
7.7.3 FUJIFILM Corporation Cancer Screening Technology Products, Services and Solutions
7.7.4 FUJIFILM Corporation Cancer Screening Technology Revenue (US$ Million) & (2019-2024)
7.7.5 FUJIFILM Corporation Recent Developments
7.8 Agilent Technologies
7.8.1 Agilent Technologies Profile
7.8.2 Agilent Technologies Main Business
7.8.3 Agilent Technologies Cancer Screening Technology Products, Services and Solutions
7.8.4 Agilent Technologies Cancer Screening Technology Revenue (US$ Million) & (2019-2024)
7.8.5 Agilent Technologies Recent Developments
7.9 Eiken Chemical
7.9.1 Eiken Chemical Profile
7.9.2 Eiken Chemical Main Business
7.9.3 Eiken Chemical Cancer Screening Technology Products, Services and Solutions
7.9.4 Eiken Chemical Cancer Screening Technology Revenue (US$ Million) & (2019-2024)
7.9.5 Eiken Chemical Recent Developments
7.10 Hitachi Chemical (Kyowa Medex)
7.10.1 Hitachi Chemical (Kyowa Medex) Profile
7.10.2 Hitachi Chemical (Kyowa Medex) Main Business
7.10.3 Hitachi Chemical (Kyowa Medex) Cancer Screening Technology Products, Services and Solutions
7.10.4 Hitachi Chemical (Kyowa Medex) Cancer Screening Technology Revenue (US$ Million) & (2019-2024)
7.10.5 Hitachi Chemical (Kyowa Medex) Recent Developments
7.11 Clinical Genomics Pty Ltd (Quest Diagnostics)
7.11.1 Clinical Genomics Pty Ltd (Quest Diagnostics) Profile
7.11.2 Clinical Genomics Pty Ltd (Quest Diagnostics) Main Business
7.11.3 Clinical Genomics Pty Ltd (Quest Diagnostics) Cancer Screening Technology Products, Services and Solutions
7.11.4 Clinical Genomics Pty Ltd (Quest Diagnostics) Cancer Screening Technology Revenue (US$ Million) & (2019-2024)
7.11.5 Clinical Genomics Pty Ltd (Quest Diagnostics) Recent Developments
7.12 Sysmex
7.12.1 Sysmex Profile
7.12.2 Sysmex Main Business
7.12.3 Sysmex Cancer Screening Technology Products, Services and Solutions
7.12.4 Sysmex Cancer Screening Technology Revenue (US$ Million) & (2019-2024)
7.12.5 Sysmex Recent Developments
7.13 QIAGEN
7.13.1 QIAGEN Profile
7.13.2 QIAGEN Main Business
7.13.3 QIAGEN Cancer Screening Technology Products, Services and Solutions
7.13.4 QIAGEN Cancer Screening Technology Revenue (US$ Million) & (2019-2024)
7.13.5 QIAGEN Recent Developments
7.14 R-Biopharm
7.14.1 R-Biopharm Profile
7.14.2 R-Biopharm Main Business
7.14.3 R-Biopharm Cancer Screening Technology Products, Services and Solutions
7.14.4 R-Biopharm Cancer Screening Technology Revenue (US$ Million) & (2019-2024)
7.14.5 R-Biopharm Recent Developments
7.15 Immunostics
7.15.1 Immunostics Profile
7.15.2 Immunostics Main Business
7.15.3 Immunostics Cancer Screening Technology Products, Services and Solutions
7.15.4 Immunostics Cancer Screening Technology Revenue (US$ Million) & (2019-2024)
7.15.5 Immunostics Recent Developments
8 Industry Chain Analysis
8.1 Cancer Screening Technology Industrial Chain
8.2 Cancer Screening Technology Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Cancer Screening Technology Sales Model
8.5.2 Sales Channel
8.5.3 Cancer Screening Technology Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Abbott
BD
Siemens Healthineers
GE Healthcare
F. Hoffmann-La Roche
Olympus Corporation
FUJIFILM Corporation
Agilent Technologies
Eiken Chemical
Hitachi Chemical (Kyowa Medex)
Clinical Genomics Pty Ltd (Quest Diagnostics)
Sysmex
QIAGEN
R-Biopharm
Immunostics

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.